Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
Relay Therapeutics (Nasdaq: RLAY) has announced that it will report its third quarter 2021 financial results on November 10, 2021, after market closure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) has announced that it will report its third quarter 2021 financial results on November 10, 2021, after market closure. No accompanying teleconference will be held. The company specializes in precision medicine and is focused on enhancing drug discovery, particularly in targeted oncology and genetic diseases, using its proprietary Dynamo™ platform that integrates advanced computational and experimental technologies.
Positive
- Focus on precision medicine and innovative drug discovery.
- Dynamo™ platform aims to address previously intractable protein targets.
Negative
- None.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was -2.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 financial results after the close of market on Wednesday, November 10, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. Relay Therapeutics’ Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
Senior Vice President, Corporate Affairs and Investor Relations
617-322-0715
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.